Completion of enrollment in 164 patient MS clinical trial
Posted: Wed Mar 14, 2012 5:04 am
Completion of enrollment in 164 patient clinical trial of oral Trimesta(TM) for MS
Synthetic Biologics, Inc. announced today that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta(TM)) for the treatment of relapsing-remitting multiple sclerosis (MS). With over $8 million in external grant funding awarded to date, this Trimesta clinical trial should be fully funded to its completion.
"The completion of patient enrollment into the Phase II Trimesta trial represents another important milestone for oral estriol and brings us one step closer to offering a new oral treatment option to patients with relapsing-remitting MS," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "As an oral therapy with a promising clinical profile, Trimesta is expected to be extremely well positioned to provide an important treatment option for this debilitating disease.".. Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1878
Synthetic Biologics, Inc. announced today that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta(TM)) for the treatment of relapsing-remitting multiple sclerosis (MS). With over $8 million in external grant funding awarded to date, this Trimesta clinical trial should be fully funded to its completion.
"The completion of patient enrollment into the Phase II Trimesta trial represents another important milestone for oral estriol and brings us one step closer to offering a new oral treatment option to patients with relapsing-remitting MS," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "As an oral therapy with a promising clinical profile, Trimesta is expected to be extremely well positioned to provide an important treatment option for this debilitating disease.".. Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1878